GlassScriptPhysician profile
Allen Segal
NPI 1497730220
$3,599.69
in general payments reported to CMS, 2019-2025
27 companies · $1,395 in 2025
The $1,395 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $551 · 2020: $60.81 · 2021: $16.58 · 2022: $107 · 2023: $478 · 2024: $991 · 2025: $1,395.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,801 · Education: $62.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,800.73 |
| Education | $62.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $771.33 | 2019-2025 | Tavneos, Enbrel, Evenity |
| Pfizer INC. | $360.69 | 2019-2025 | |
| Abbvie INC. | $292.74 | 2019-2025 | Rinvoq, Skyrizi |
| Janssen Biotech, INC. | $266.75 | 2024-2025 | Tremfya |
| Ucb, INC. | $264.99 | 2023-2025 | Bimzelx, Cimzia |
| Mallinckrodt Hospital Products INC. | $255.85 | 2024-2025 | Acthar |
| Genentech USA, INC. | $235.25 | 2019-2025 | Actemra |
| Radius Health, INC. | $168.96 | 2019-2025 | Tymlos |
| E.R. Squibb & Sons, L.L.C. | $161.95 | 2019-2025 | Orencia |
| Glaxosmithkline, LLC. | $155.94 | 2019-2025 | Benlysta, Nucala |
| Alexion Pharmaceuticals, INC. | $148.88 | 2022-2025 | Strensiq |
| Lilly USA, LLC | $113.61 | 2023-2024 | Taltz |
| Sandoz INC. | $59.24 | 2024-2025 | Hyrimoz |
| Ani Pharmaceuticals, INC. | $55.19 | 2025 | Purified Cortrophin Gel |
| Novo Nordisk INC | $47.82 | 2019-2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aurinia Pharma U.S., INC. | $35.60 | 2023-2024 | Lupkynis |
| Sobi, INC | $29.79 | 2025 | |
| Bausch Health US, LLC | $23.00 | 2019 | |
| Novartis Pharmaceuticals Corporation | $22.42 | 2024 | |
| Almatica Pharma LLC | $22.40 | 2025 | Teriparatide |
| Corcept Therapeutics | $20.65 | 2025 | Korlym |
| Astrazeneca Pharmaceuticals LP | $19.54 | 2023 | Saphnelo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.20 | 2024 | Cyltezo |
| Invivyd INC | $14.31 | 2025 | Pemgarda |
| Amarin Pharma, INC. | $12.85 | 2019 | |
| Antares Pharma, INC. | $12.14 | 2019 | |
| Sanofi Pasteur INC. | $11.60 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allen Segal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.